Qiagen

Healthy Q2; profitability guidance upgraded

01/08/24 -"Q2 profitability was above the street’s expectations. A decent performance across most of the segments was offset by a weaker showing from Genomics/NGS. While the 2024 sales guidance was impacted by ..."

PDF page sample
Pages
62
Language
English
Published on
01/08/24
Download
You may also be interested by these reports :
06/11/25
DiaSorin’s Q3 results did not meet expectations, with all segments underperforming except for immunodiagnostics. As a result, management has lowered ...
06/11/25
Smith & Nephew reported Q3 2025 underlying revenue growth of 5.0%, missing the analyst consensus expectation of approximately 6.2% and reflecting a ...
06/11/25
Siemens Healthineers’ Q4 results fell short of the company-compiled consensus. Although sales increased in Q4, growth was lower compared to previous ...
05/11/25
Demant’s Q3 organic sales slightly exceeded expectations, driven by growth in hearing care and hearing aids, though partially offset by weakness in ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO